Efficacy News and Research

RSS

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

Although levodopa remains the "gold standard" to effectively control motor deficits in the treatment of early stage Parkinson's disease (PD), it loses effectiveness as the disease progresses. After four to six years of treatment with oral medications for Parkinson's disease, about 40% of patients experience lack of muscle control (dyskinesias), end-of-dose wearing off, and fluctuations in "On/Off" states.

27 Feb 2015

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis.

26 Feb 2015

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital.

26 Feb 2015

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK.

26 Feb 2015

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announced today that the U.S. Food and Drug Administration approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015.

26 Feb 2015

MR Solutions adds new 4.7T system to cryogen-free, preclinical MRI imaging family

A new addition to the cryogen-free, preclinical MRI imaging family, the 4.7T model, is now available to order. It joins the 3T and 7T systems for superior soft tissue contrast and molecular imaging research. This has been brought to the market by MR Solutions, the world’s largest independent developer and manufacturer of commercially available MRI technology.

From MR Solutions 26 Feb 2015

Researchers generate mature, functional skeletal muscles using new approach

A team of researchers from Italy, Israel and the United Kingdom has succeeded in generating mature, functional skeletal muscles in mice using a new approach for tissue engineering. The scientists grew a leg muscle starting from engineered cells cultured in a dish to produce a graft.

25 Feb 2015

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).

25 Feb 2015

Researchers develop revolutionary approach to treat drug-resistant tumors

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy.

25 Feb 2015

Direct brain responsive neurostimulator reduces seizures, improves quality of life

Piotr Olejniczak, MD, PhD, LSU Health New Orleans Professor of Neurology and Director of the Epilepsy Center, contributed to a study of the long-term effectiveness of the first direct brain responsive neurostimulator for partial onset, or focal, seizures that cannot be controlled with medication.

25 Feb 2015

PCDS AC system optimizes delivery of anticoagulation drugs, reduces adverse events

Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation drugs and reduces adverse events associated with anticoagulation therapy. The software was designed and developed in collaboration with leading clinical thrombosis experts, and is a decision support tool that takes the complexity out of AC management by providing a real-time AC dashboard. With intuitive, predictive clinical decision support, PCDS AC transforms evidence-based guidelines into intelligent tools that measure and improve AC therapy outcomes.

25 Feb 2015

Patients battling sleep apnea find relief from Zzoma device

Thousands of patients in the U.S. and Europe battling positional obstructive sleep apnea (OSA) are finding relief from Zzoma, an FDA-cleared medical device designed by physicians at Sleep Specialists, LLC.

25 Feb 2015

PCF announces Challenge Awards to support research on new treatment strategies for prostate cancer

The Prostate Cancer Foundation (PCF) announces 3 new Challenge Awards to support discoveries for the treatment of lethal prostate cancer.

25 Feb 2015

Kuros Biosurgery granted U.S. patent for synthetic hydrogel technology

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced today that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947.

24 Feb 2015

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat inhaler from five Phase III trials from the UniTinA-asthma program at the 2015 American Academy of Allergy, Asthma & Immunology Annual Meeting in Houston, Texas.

24 Feb 2015

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.

23 Feb 2015

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient.

23 Feb 2015

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced the New Drug Application (NDA) for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), has been accepted for review by the U.S. Food and Drug Administration.

23 Feb 2015

NUS, Washington University jointly open new research institute to address social challenges

The National University of Singapore Faculty of Arts and Social Sciences has partnered the Washington University in St. Louis to set up a dedicated research institute - the Next Age Institute (NAI) - to study, design and test social innovations to address complex social issues surrounding families, communities and societies in Singapore and around the world.

23 Feb 2015

Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix™, a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores).

23 Feb 2015

Efficacy News and Research

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

MR Solutions adds new 4.7T system to cryogen-free, preclinical MRI imaging family

Researchers generate mature, functional skeletal muscles using new approach

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Researchers develop revolutionary approach to treat drug-resistant tumors

Direct brain responsive neurostimulator reduces seizures, improves quality of life

PCDS AC system optimizes delivery of anticoagulation drugs, reduces adverse events

Patients battling sleep apnea find relief from Zzoma device

PCF announces Challenge Awards to support research on new treatment strategies for prostate cancer

Kuros Biosurgery granted U.S. patent for synthetic hydrogel technology

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

NUS, Washington University jointly open new research institute to address social challenges

Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News